On 29 March, 2019, tumor marker product: Carbohydrate Antigen 50 diagnostic kit  (Chemiluminescent Microparticle Immunoassay) achieved medical device registration certificate.

About product:

This kit is used to quantitatively detect the carbohydrate antigen 50 (CA50) in human serum. It is mainly used to dynamically monitor patients with malignant tumors to assist to determine disease progression or treatment effect. However, it cannot be used as an early diagnosis or diagnostic basis for malignant tumors and tumor screening in the general population.

It is mainly used to dynamically monitor patients with malignant tumors to assist to determine disease progression or treatment effect. However, it cannot be used as an early diagnosis or diagnostic basis for malignant tumors and tumor screening in the general population.

To know about product:

CA50 is a ganglioside antigen with sialic acid glycoprotein and sialic acid sugar ester as the main components, which is a non-specific broad-spectrum carbohydrate antigen. CA50 is only detected in the pancreas in normal tissues. When cells become malignant, due to the inactivation of glycosyl invertase or the reactivation of invertase during the embryonic period, the carbohydrate structure on the cell surface changes and the antigenic properties change, resulting in the production of tumor markers. Elevated CA50 levels can be seen in patients with malignant tumors, such as gastric cancer, liver cancer, colorectal cancer, lung cancer, gallbladder cancer, uterine cancer, ovarian cancer, renal cancer, or breast cancer, especially in patients with pancreatic cancer. In addition, patients with ulcerative colitis, cirrhosis, benign obstructive jaundice, benign liver disease, benign biliary tract disease, melanoma, lymphoma or autoimmune disease also have elevated CA50. Because of its dual recognition to Lewis antigen-negative and -positive tumors, CA50 is a tumor marker with much broader spectrums than CA19-9. Tumor diagnosis should not only be made from the test results of CA50, but should be comprehensively judged in combination with the patient's clinical signs, medical history and other test results.